Latest Breaking News On - Oncology business unit - Page 7 : comparemela.com

AstraZeneca rallies as results show Tagrisso slows lung cancer progression

AstraZeneca rallies as results show Tagrisso slows lung cancer progression
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

Dave-fredrickson
Drug-administration
New-england-journal
Oncology-business-unit

AstraZeneca's Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit.

China
United-states
Canada
Switzerland
Australia
Japan
American
Dave-fredrickson
Laurie-ambrose
American-cancer-society
Pathology-lab
Drug-administration

Osimertinib With Chemo Gains FDA Approval for EGFR-Mutated NSCLC

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy.

United-states
American
Dave-fredrickson
Astra-zeneca
Astrazeneca
American-society-of-clinical-oncology
Dana-farber-cancer-institute
New-england-journal
Oncology-business-unit
American-society
Nsclc
Osimertinib

FTSE 100 approaches six-month high; AstraZeneca, Rolls-Royce risers

FTSE 100 approaches six-month high; AstraZeneca, Rolls-Royce risers
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

United-kingdom
Ukraine
Russia
Germany
London
City-of
Red-sea
Djibouti-general
Djibouti
Texas
United-states
Sudan

FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC

Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.

Davida-litman
Dave-fredrickson
Astrazeneca
Dana-farber-cancer-institute
Osimertinib-with
Line-treatment
Completion-date
Oncology-business-unit
Thenew-england-journal
Yang-jc-h
Mutated-advanced